



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---------------------------------|-------------|-----------------------------|---------------------|------------------|
| 10/840,041 | 05/06/2004 | Fabrizio Alessandro Maspero | 1032553-000059 | 7765 |
| 21839 | 7590 | 06/17/2010 | | |
| BUCHANAN, INGERSOLL & ROONEY PC | | | EXAMINER | |
| POST OFFICE BOX 1404 | | | RAMANA, ANURADHA | |
| ALEXANDRIA, VA 22313-1404 | | | ART UNIT | PAPER NUMBER |
| | | | 3775 | |
| | | | | |
| | | | NOTIFICATION DATE | DELIVERY MODE |
| | | | 06/17/2010 | ELECTRONIC |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ADIPFDD@bipc.com
offserv@bipc.com

| | | |
|------------------------------|--------------------------------------|---------------------------------------|
| Office Action Summary | Application No. 10/840,041 | Applicant(s) MASPERO ET AL. |
| | Examiner Anu Ramana | Art Unit 3775 |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on **24 March 2010**.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) **1-12, 15, 16 and 41-64** is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) **1-12, 15, 16 and 41-64** is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/SB/06)
 Paper No(s)/Mail Date _____
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____
- 5) Notice of Informal Patent Application
 6) Other: _____

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 41, 43-45, 55, 63 and 64 are rejected under 35 U.S.C. 102(e) as being anticipated by Evans et al. (US 7,241,316).

Evans et al. disclose a moldable implant composition including: a plurality of biocompatible synthetic non-bone particles such as ceramics or calcium phosphate or calcium sulfate having a particle size of about 100 microns; a biocompatible polymer such as polylactide or polycaprolactone; a plasticizer such as caprolactone; and a biologically active substance such as a growth factor wherein the composition can be delivered by injection or preformed as an implant for surgical insertion (Figs. 15-18, col. 16, lines 20-61, col. 18, lines 63-67, col. 19 and col. 20, lines 1-51).

Regarding claim 55, it is noted that Evans et al. discloses particles having a particle size of about 100 microns, i.e., regularly-sized particles.

Regarding claims 63 and 64, it is noted that Evans et al. discloses a specific value of particle size of about 100 microns, which is within the claimed ranges of "of about greater than 10 microns to about 2000 microns" and "of about 100 microns to about 500 microns". It is noted that a specific example in the prior art which is within a claimed range anticipates the range. MPEP 2131.03.

Claims 43-45, 55, 63 and 64 are rejected under 35 U.S.C. 102(e) as being anticipated by Ricci et al. (US 6,770,695).

Ricci et al. disclose an implantable or moldable composition including: synthetic calcium sulfate particles having a size greater than 20 microns; a biocompatible or biodegradable polymeric coating on the particles wherein the polymer is any type of resorbable polymer (for e.g. polylactides, polydixanones etc.), the weight of the polymer is about 0.1% to about 50% by weight and the thickness of the polymeric coating is 0.5 microns to 100 microns; a plasticizer such as acetone; and a setting agent such as water or saline (col. 3, lines 11-28 and col. 4, lines 5-47). Once solidified in a bone defect, the Ricci et al. composition forms a composite matrix with pores filled with air.

Regarding claim 55, it is noted that Ricci et al. disclose particles having a size (underline, emphasis added) greater than 20 microns, i.e., regularly-sized particles.

Regarding claims 63 and 64, it is noted that Ricci et al. discloses a specific value of particle size, i.e., a size greater than 20 microns, which is within the claimed ranges "of about greater than 10 microns to about 2000 microns" and "of about 100 microns to about 500 microns". It is noted that a specific example in the prior art which is within a claimed range anticipates the range. MPEP 2131.03.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-3, 5-9, 11-12, 16, 41-42, 46-54 and 56-62 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ricci et al. (US 6770695).

Ricci et al. disclose an implantable or moldable composition including: synthetic calcium sulfate particles having a size greater than 20 microns; a biocompatible or biodegradable polymeric coating on the particles wherein the polymer is any type of resorbable polymer (for e.g. polylactides, polydixanones etc.), the weight of the polymer

is about 0.1% to about 50% by weight and the thickness of the polymeric coating is 0.5 microns to 100 microns; a plasticizer such as acetone; and a setting agent such as water or saline (col. 3, lines 11-28 and col. 4, lines 5-47).

Ricci et al. disclose particles with a size greater than 20 microns. Ricci et al. also disclose the weight of the polymer to be about 0.1% to about 50% by weight.

Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to have provided particles with sizes in a range of about 100 microns to about 4000 microns, since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. In re Aller, 105 USPQ 233.

Further, it would have been obvious to one having ordinary skill in the art at the time the invention was made to have provided polymer in a range of about 4% to about 20% by weight, since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. In re Aller, 105 USPQ 233.

Additionally, it would have been obvious to one having ordinary skill in the art at the time the invention was made to have provided a polymeric coating thickness in a range of about 1 micron to about 300 microns, since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. In re Aller, 105 USPQ 233.

Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Ricci et al. in view of Evans et al. (US 7,241,316).

Ricci et al. disclose all elements of the claimed invention except for alternate types of biocompatible ceramics.

Evans et al. teach the use of biocompatible ceramics such as various calcium phosphate salts (col. 20, lines 21-51).

The substitution of one known ceramic (various types of calcium phosphate) for another known ceramic (calcium sulfate as disclosed by Ricci et al.) would have been obvious to one of ordinary skill in the art at the time of the invention since this amounts

Art Unit: 3775

to simple substitution of one known ceramic for another and would have yielded predictable results, namely, a biocompatible, implantable composition.

Claim 10 is rejected under 35 U.S.C. 103(a) as being unpatentable over Ricci et al. in view of Meredith (US 7,001,551).

Ricci et al. disclose all elements of the claimed invention except for a biologically active substance.

It is well known to use a biologically active substance such as a growth factor in an implantable composition to enhance bone growth into a bone defect, as evidenced by Meredith (col. 9, lines 53-67 and col. 10, lines 1-26).

Therefore, it would have been recognized by one of ordinary skill in the art that applying the known technique of providing a biologically active substance such as a growth factor, taught by Meredith, in the Ricci et al. implantable composition would have yielded predictable results, i.e., improved repair of a bone defect by enhancing bone growth to seal the defect.

Claim 15 is rejected under 35 U.S.C. 103(a) as being unpatentable over Ricci et al. in view of Smestad (US 4430760).

Ricci et al. disclose all elements of the claimed invention except for the use of a microporous membrane.

It is well known to use a porous casing or membrane to contain filling material used to repair a bone defect, as evidenced by Smestad (col. 2, lines 57-68 and col. 3, lines 1-57).

Therefore, it would have been recognized by one of ordinary skill in the art that applying the known technique of providing a porous casing, as taught by Smestad, to hold the Ricci et al. material would have yielded predictable results, i.e., containment having a desired shape and size for sealing a bone defect.

Claim 42 and 46 are rejected under 35 U.S.C. 103(a) as being unpatentable over Evans et al. (US 7241316).

Evans et al. disclose all elements of the claimed invention except for the claimed weight percentage of the biocompatible polymer to be about 4% to about 20%.

It would have been obvious to one having ordinary skill in the art at the time the invention was made to have provided the claimed weight percentages of biocompatible polymer, since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. In re Aller, 105 USPQ 233.

Response to Arguments

Applicant's arguments have been fully considered by the examiner but are not persuasive for the following reasons.

Regarding the rejections under 35 USC 102(e) over Evans et al., the examiner reiterates, "at least a portion of each granule or particle" of Evans et al. would be coated with polymer when the non-polymeric granules are mixed with a polymer and the plasticizer.

Regarding the rejections under 35 U.S.C. 102(e) over Ricci et al. (or Ricci herein), applicant's arguments that the implant mass of Ricci et al. is not plastically deformable are not persuasive. Prior to setting or hardening, the Ricci et al. implant mass or structural matrix would be plastically deformable.

The examiner maintains that Ricci et al. has a structural matrix that is formed by granules bound together, at least, in part, (underline, emphasis added) by a biocompatible polymer coating formed on each granule. Prior to implantation, the structural matrix of Ricci et al. does not contain any bone particles. Regarding, the limitation "an open porous region comprising macropores," the Ricci et al. composite matrix, immediately after implantation, meets this limitation. Initially after implantation, the Ricci et al. composite matrix has no bone particles because bone growth has not yet occurred. A porous system is formed by resorption of calcium sulfate. It is the

Art Unit: 3775

examiner's position that at least initially after implantation (one to two weeks), the Ricci et al. composite matrix is porous without bone particles because bone growth has not yet occurred.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anu Ramana whose telephone number is (571) 272-4718. The examiner can normally be reached Monday through Friday between 8:00 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thomas Barrett can be reached at (571) 272-4746. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3775

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

AR
June 11, 2010

/Anu Ramana/
Primary Examiner, Art Unit 3775